France’s Aventis said on Monday its shareholders faced a huge risk if they accepted a hostile bid from Sanofi-Synthelabo before the result of a patent trial on its rival’s biggest drug.The strength of the U.S. patent on Sanofi’s blockbuster blood thinner Plavix was a key unknown for investors considering the 48 billion euro ($61.2 billion) stock-and-cash offer, said Aventis Chief Operating Officer Richard Markham.
